Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab combined chemotherapy for children and AYAs with localized mature B-cell lymphoma
jRCTs041210104Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in mature B-cell lymphoma, Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 3-year event-free survival rate in intermediate-risk patients under 18 years old. Started Dec 2021; status: recruiting.
02
Drugs
rituximab
03
Conditions
mature B-cell lymphomaBurkitt lymphoma (BL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCTs041210104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210104.